Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31202904 | 0.82 | KDM4E (0.55) | KDM4EALDH1A1GAAHTTNR0B1 | |
| SCHEMBL9867135 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1GAAHTTNR0B1 | |
| SCHEMBL4244153 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1GAAHTTNR0B1 | |
| SCHEMBL28649647 | 0.79 | SMN1; SMN2 (0.40) | KDM4EALDH1A1GAANR0B1MEN1 | |
| SCHEMBL4246617 | 0.75 | FFAR3 (0.38) | KDM4EFFAR3GAA | |
| SCHEMBL4248362 | 0.74 | ALDH1A1 (0.34) | KDM4EALDH1A1GAANR0B1KMT2A | |
| SCHEMBL4237629 | 0.72 | KMT2A (0.44) | KDM4EALDH1A1GAAHTTNR0B1 | |
| SCHEMBL4244260 | 0.72 | KMT2A (0.54) | KDM4EALDH1A1NR0B1MEN1KMT2A | |
| SCHEMBL13743994 | 0.70 | PGR (0.46) | ALDH1A1HTTMEN1KMT2APOLB | |
| SCHEMBL4240492 | 0.70 | HPGD (0.50) | ALDH1A1GAAHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011589-B2 | Treatments for gastrointestinal conditions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170073332-A1 | Treatments for Gastrointestinal Conditions | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011589-B2 | Treatments for gastrointestinal conditions | SI, FABP2, SLC10A2 | KDM4E 4757/4885FFAR3 3903/4885ALDH1A1 2166/4885 |
| US-20170073332-A1 | Treatments for Gastrointestinal Conditions | SI, FABP2, SLC10A2 | KDM4E 4757/4885FFAR3 3903/4885ALDH1A1 2166/4885 |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | KDM4E 3718/4885FFAR3 3076/4885ALDH1A1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.